Brief: Arrowhead Pharmaceuticals Q1 EPS USD 0.22
05/02/2026 21:05
Feb 05 (Reuters) - Arrowhead Pharmaceuticals Q1 operating expenses USD 223.224 million. Q1 net income USD -2.569 million Q1 operating income USD 40.809 million Q1 revenue USD 264.033 million vs. IBES estimate USD 270.1 million
Recent news on Arrowhead Pharmaceuticals
See all newsBrief: Uk's MHRA Authorises Redemplo For Adults With Familial Chylomicronaemia Syndrome
US STOCKS ON THE MOVE-Netflix, Coinbase Global, Accenture
US STOCKS ON THE MOVE-Bending Spoons, Skydance, Albertsons
US STOCKS ON THE MOVE-Albertsons, GlobalFoundries, American Electric Power, Fastenal
Brief: Arrowhead Pharmaceuticals Announces ARO-MAPT Interim Phase 1/2a Clinical Data Demonstrating Deep and Durable Tau Reductions in Healthy Volunteers